Another Genmab drug from Janssen receives breakthrough therapy designation
The US FDA has given breakthrough therapy status to the cancer drug teclistamab which is based on Genmab's Duobody platform.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Shortly after Janssen secured approval from the US Food and Drug Administration (FDA) for the Genmab-developed lung cancer drug Rybrevant, the pharmaceutical company has taken a crucial step with another drug from Genmab's Duobody platform.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
